key: cord-0829539-8m8h8mew
authors: Cavalcante, Marcelo Borges; de Melo Bezerra Cavalcante, Candice Torres; Cavalcante, Ana Nery Melo; Sarno, Manoel; Barini, Ricardo; Kwak-Kim, Joanne
title: COVID-19 and miscarriage: from immunopathological mechanisms to actual clinical evidence
date: 2021-09-10
journal: J Reprod Immunol
DOI: 10.1016/j.jri.2021.103382
sha: a83c8f25032bbfc42a0cae3b40dd67b74bc86514
doc_id: 829539
cord_uid: 8m8h8mew

The association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the first half of pregnancy and pregnancy loss is still unknown. Infections by other coronaviruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), appear to increase the risk of miscarriage. The purpose of this study is to assess whether SARS-CoV-2 infection increases the risk of miscarriage. Firstly, a narrative review of the literature on animal and human studies was performed to analyze the immunopathological mechanisms of SARS-CoV-2 infection during preconception and early pregnancy, by which it may increase the risk of miscarriage. Secondly, a systematic review/meta-analysis of studies was conducted to assess the prevalence of miscarriage in COVID-19 patients diagnosed during pregnancy. Meta-analysis of proportions was used to combine data, and pooled proportions were reported. Seventeen case series and observational studies and 10 prevalence meta-analyses were selected for the review. The estimate of the overall miscarriage rate in pregnant women with COVID-19 was 15.3% (95% CI 10.94 to 20.59) and 23.1 (95% CI 13.17 to 34.95) using fixed and random effect models, respectively. Based on the data in the current literature, the miscarriage rate (<22 weeks gestation) in women with SARS-CoV-2 infection is in the range of normal population. Well-designed studies are urgently needed to determine whether SARS-CoV-2 infection increases the risk of miscarriage during periconception and early pregnancy.

Phone/Fax: +55-85-34773000 E-mail: marcelocavalcante.med@gmail.com

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 , has been rapidly spreading all over the world, prompting the world health organization (WHO) to declare a pandemic on March 11, 2020 ). COVID-19 had affected more than 170 million people worldwide, with a total of more than 3.5 million deaths ((WHO) 2021) by the end of May 2021.

During the pandemic, treatment protocols have been rapidly established with the development of new drugs, including anti-SARS-CoV-2 monoclonal antibodies and antiviral medications (Mishra and Tripathi 2021) , and several COVID-19 vaccines have been introduced to prevent the spread of COVID-19. However, due to the safety concerns and difficulties in accessing vaccines, vaccine rollout has been slower than expected, and there are substantial regional differences in vaccination rates. In the U.S. and U.K., herd J o u r n a l P r e -p r o o f immunity is expected most likely by the third quarter of 2021 with improved vaccine supply. However, the emergence of SARS-CoV-2 variants and a possible fourth wave of Covid-19 may delay the timeline. Unfortunately, herd immunity may present temporary or limited regions. Therefore, we will face nationwide or regional herd immunity in the next few years, which can be temporary, or endemicity of COVID-19 (Sarun Charumilind 2021) .

Predominantly, SARS-CoV-2 is transmitted through the respiratory route, with the virus suspended on droplets, or less commonly, aerosols. Other routes of transmission (from domestic pets and farm animals, fecal-oral, vertical, sexual, and blood-borne transmission) have already been studied and found to have little or no impact on disease spread (Meyerowitz et al. 2021) . SARS-CoV-2 infection can occur without any clinical manifestation, with studies revealing varying proportions of asymptomatic patients ranging from 33% to 89% of laboratory-diagnosed cases. COVID-19 can cause mild or moderate disease in 81% of cases, severe disease in 14% of cases, and critical illness in 5% of patients, with the mortality rate being 2.3% (Wu and McGoogan 2020) .

Pregnant women are at a higher risk of severe COVID-19-related illness. Pregnant women are more likely to be admitted to an intensive care unit (ICU) compared to nonpregnant women (10.5 versus 3.9 per 1,000 cases; adjusted risk ratio [aRR] = 3.0; 95% confidence interval [CI] = 2.6-3.4), to receive invasive ventilation (2.9 versus 1.1 per 1,000 cases; aRR = 2.9; 95% CI = 2.2-3.8) and extracorporeal membrane oxygenation (ECMO) (0.7 versus 0.3 per 1,000 cases; aRR = 2.4; 95% CI = 1.5-4.0), and to die (1.5 versus 1.2 per 1,000 cases; aRR = 1.7; 95% CI = 1.2-2.4) (Zambrano et al. 2020) .

However, the effect of COVID-19 on the first half of pregnancy has not been investigated well.

For decades, scientists have debated the association between viral infection and miscarriage. Among the known causes of miscarriage, chromosomal abnormalities, such as aneuploidy or triploidy, account for half of the cases, while obesity, endocrinopathies, thrombophilia (acquired or inherited), uterine anatomical abnormalities, and infections account for the other half (Pinar et al. 2018) . During previous outbreaks of other coronaviruses, an increased risk of miscarriage has been reported in pregnant women with SARS-CoV and MERS-CoV. At the beginning of the COVID-19 pandemic, the potential obstetrical risk of pregnant women infected with SARS-CoV-2 was projected, considering a miscarriage rate (57%, 4/7) observed in pregnant women infected with other coronaviruses, such as SARS -CoV (Favre et al. 2020) , and the fact that the direct action of the virus or maternal immunological responses to the viral infection may cause trophoblast and placental damage (Giakoumelou et al. 2016) . However, the first study on pregnant women with COVID-19 found no increased risk of miscarriage among these patients (Yan et al. 2020) .

In this study, we aim to review possible immunopathological mechanisms of COVID-19 which may lead to pregnancy losses based on the literature of animal and human studies during the preconception period and the first half of pregnancy, and the current evidence of the COVID-19-impact on pregnancy losses by conducting a systematic review by a meta-analysis of studies that assessed the prevalence of miscarriages in pregnant women with COVID-19.

The SARS-CoV-2 virus is an enveloped positive-strand RNA virus. There are approximately 29 different viral proteins identified; the most important ones are the nucleocapsid (N), membrane (M), spike (S), and envelope (E) proteins. The capsid was formed outside the genome by N protein, and the genome is further packed by an envelope associated with structural proteins (M protein, S protein, and E protein) (Wang et al. 2020a ). The angiotensin-converting enzyme 2 (ACE2) is the host receptor for SARS-CoV-2 cell entry. The S proteins are distributed uniformly on the virus surface, allowing for greater interaction with ACE2. After binding to ACE2, the cellular transmembrane serine protease 2 (TMPRSS2), located on the host cell membrane, promotes virus entry into the cell by activating the S protein (Wang et al. 2020a ).

Initially, SARS-CoV-2 infects nasal epithelial cells and then spreads to bronchial epithelium and alveolar epithelial type II cells, which have ACE2 and TMPRSS2 expression. After reaching the pneumocytes, in moderate/severe forms of COVID-19, an intense viral replication occurs, triggering local and systemic immune responses (Wang et al. 2020a) . COVID-19 transmission and severity appear to be related to viral load in the upper and lower respiratory tracts, respectively (Cevik et al. 2021) . Typically, viral respiratory pneumonia with critical hypoxemia is the most common clinical manifestation of severe COVID-19. During the acute phase of the disease, COVID-19 usually affects other organs, either directly or through systemic complications of the intense pulmonary inflammatory response known as a cytokine storm (Wang et al. 2020a ).

Interestingly, studies have revealed that a variety of extrapulmonary organs are potential binding targets for SARS-CoV-2. Furthermore, ACE2 proteins are expressed at J o u r n a l P r e -p r o o f various levels in organs such as the heart, kidney, liver, digestive tract, and brain (Dong et al. 2020) . For decades, researchers have described the expression of ACE2 and TMPRSS2 in the endometrium, embryo, and various cell types of the human placenta, including syncytiotrophoblast, villous cytotrophoblasts, invasive and intravascular trophoblast, decidual cells, vascular smooth muscle of primary villi, and umbilical arterial and venous endothelium (Valdés et al. 2006 , Vaz-Silva et al. 2009 , Weatherbee et al. 2020 . Recently, the expression of ACE2 and TMPRSS2 was detected in human trophectoderm from early embryos as well as in all three trimesters of pregnancy (Cui et al. 2021 ). On the other hand, ACE2 and TMPRSS2 expression was negatively correlated with gestational age, with ACE2 and TMPRSS2 being highly expressed in first trimester trophoblastic tissues and little expressed or undetectable in the third-trimester placenta (Bloise et al. 2021) . Therefore, the preconception and early pregnancy uterine environments are potentially vulnerable to SARS-CoV-2 infection. Thus, the occurrence of COVID-19 during the periconceptional period may increase the risk of miscarriage.

The renin-angiotensin system (RAS) is composed of a set of peptides, enzymes and receptors involved in the pregnancy process. The components of the RAS are distributed throughout the uteroplacental unit. Angiotensinogen, renin, ACE, angiotensin I, angiotensin II and angiotensin receptors (type 1 and type 2) are found in the placenta, uterus (endometrium and myometrium), fetal membranes and amniotic fluid. In early pregnancy, high levels of estrogens stimulate hepatic production of angiotensinogen, consequently raising plasma and uterine levels. Studies have shown that changes in the RAS are related to obstetric complications such as pre-eclampsia (Qi et al. 2020; Anton and Brosnihan, 2008) .

ACE2 and TMPRSS2 are highly expressed in human endometrial stromal cells during the secretory phase and required for decidualization of human endometrial stromal J o u r n a l P r e -p r o o f cells (Vaz-Silva et al. 2009 ). In addition, ACE2 is also an important component of the human placental renin-angiotensin system (RAS), which is upregulated in the first trimester and involved in endometrial neovascularization during the peri-implantation period as well as placental development (Qi et al. 2020) . Throughout pregnancy, the expression of the placental RAS is decreased. When recurrent miscarriage women were compared to fertile women, the expression of RAS components was found to be dysregulated (Qi et al. 2020) . The SARS-CoV-2-ACE2 complex negatively regulates ACE2, resulting in a decrease in plasma levels of angiotensin-(1-7), which, in turn, potentiates vasoconstriction and the hypercoagulable state, contributing to reproductive failures and other obstetrical complications (Narang et al. 2020 ).

Increased risk of embryo implantation failure and miscarriage has been reported during the periconceptional period in women with COVID-19. It was speculated that the reproductive failure was due to systemic inflammation and interference with trophectoderm-endometrium molecular signaling rather than a direct action of SARS-CoV-2 at the implantation site (Sills and Wood 2020) . The immunopathology of COVID-19, accompanied by high levels of IL-6, IL-8, TNF-alpha, and other cytokines, would result in unbalanced Th1/Th2 immune responses. Consequently, the "cytokine storm" of COVID-19 induces a hypercoagulable state that is detrimental to normal in-utero blastocyst/fetal development (toxic endometrial microenvironment and hypoperfusion secondary to microthrombus formation), as well as an unfavorable uterine immune response to embryo implantation (Sills and Wood 2020) . Indeed, abnormalities in the maternal immune response during peri-implantation and early pregnancy, with a predominant pro-inflammatory response (Th1 and Th17), and thrombophilic conditions have been linked to recurrent implantation failure and miscarriage (Yang et al. 2010 , Kwak-Kim et al. 2014 , Liu et al. 2020 ).

SARS-CoV-2 has been found in various body fluids (Bora et al. 2020) , including blood (Chang et al. 2020 , Wang et al. 2020b , cerebrospinal fluid (Huang et al. 2020 , Moriguchi et al. 2020 , pericardial fluid (Farina et al. 2020) , pleural fluid (Mei et al. 2020 ), urine (Zheng et al. 2020) , semen (Li et al. 2020) , saliva , and eye tissues (Bora et al. 2020 , Xie et al. 2020 . Plasma SARS-CoV-2 RNA was detected in 27% of hospitalized participants and 13% of outpatients with COVID-19. Furthermore, the viral load (as measured by a nasopharyngeal sample, posterior oropharyngeal saliva or endotracheal aspirate or plasma) of COVID-19 patients was associated with disease severity (worse respiratory disease severity, lower absolute lymphocyte counts, and increased markers of inflammation, including C-reactive protein and IL-6) and mortality (Fajnzylber et al. 2020) . Although the dynamics of SARS-CoV-2 during the active phase of the disease need to be elucidated further, endometrial, decidual, and placental infection is possible via the hematological spread of SARS-CoV-2. Indeed, placental SARS-CoV-samples from the COVID-19 cases. Maternal vascular malperfusion (46% of cases; 95% CI 38.0%-54.0%), fetal vascular malperfusion (35.3% of cases; 95% CI 27.7%-43.0%), and evidence of inflammation in the placentas (villitis 8.7% of cases, intervillositis 5.3% of cases, chorioamnionitis 6% of cases) were the most common pathologies of affected placentas. Other placental changes observed in the second and third-trimester placentas include fibrin deposition, infarction, and vascular and intervillous thrombosis (Sharps et al. 2020) . Placental changes are more frequent in severe COVID-19 cases but have been reported in patients with mild COVID-19 and even in asymptomatic cases (Ferraiolo et al. 2020) .

A case study of a 26-year-old pregnant woman in the third trimester with one living child and a history of one first-trimester spontaneous abortion was published in August 2020. In the eighth week of pregnancy, she presented with an asymptomatic COVID-19. The ultrasound evaluation revealed a fetal demise at 13 weeks of gestation (endometrium, decidua, and trophoblast) (Fig. 1) . Moreover, the risk appears to be higher in patients with the severe form of COVID-19 but also in asymptomatic women. Based on evidence from studies prior to COVID-19 and other studies with conditions similar to SARS-CoV-2 infection, it is necessary to assess whether the current literature supports the hypothesis that SARS-CoV-2 infection in the periconception period and in the first half of pregnancy increases the risk of miscarriage.

This study aimed to systemically review the risk of miscarriage in pregnant women who had COVID-19 during the first half of their pregnancy. The review was carried out in accordance with the statement on Preferred Reporting Items for Systematic

Review and Meta-Analysis (PRISMA) (Liberati et al. 2009 , Page et al. 2021 ). The following search strategies were used to explore the PUBMED and EMBASE databases: COVID-19 or coronavirus disease 2019 or SARS-CoV-2, and miscarriage or abortion or pregnancy outcomes. The search was restricted to papers written in English.

For inclusion, articles published between December 1, 2019, and March 31, 2021, were considered. There were no attempts made to contact the study authors in order to identify missing and confusing data. Further, the EndNote X9 (Clarivate Analytics US LLC, Philadelphia, United States) was used as reference management software. In addition, a manual search of the references found in the selected articles and reviews was performed. Two reviewers (MBC and CTMBC) went over the titles and abstracts and screened duplicates independently for potential eligibility. They then read the entire text to determine final eligibility. Discrepancies were resolved through discussion and consensus, with the assistance of the third reviewer (ANMC), if necessary.

The authors, the date of publication, the study design, the total number of pregnant women, the total number of pregnant women diagnosed with COVID-19 in the first half of pregnancy, and the number of abortions were extracted. The data were initially analyzed in the form of a table using descriptive statistics.

In a meta-analysis, individual studies were pooled, and overall estimates of miscarriage prevalence were calculated using fixed and random effect models. The heterogeneity of the results was assessed using the Cochran's Q test and the I 2 inconsistency measure test. Publication bias was evaluated using Egger's and Begg's test 

In PubMed/Medline and EMBASE, the electronic search yielded 887 and 208 records, respectively. A total of 980 studies were obtained after downloading 1,095 studies to the EndNote X9 Library Program after excluding duplicate records (115 duplicate records). Following an initial evaluation of titles and abstracts, 25 studies were excluded due to non-English language and 892 for other reasons (review articles, case reports, animal research, letters, exception to the letter reporting data on miscarriage in pregnant women with COVID-19). Sixty-three publications were chosen for a full-text review, excluding forty-six original articles that did not contain data on the prevalence of miscarriage in pregnant women with COVID-19 or were literature reviews. Finally, 17 studies were evaluated in the systematic review (6 case series studies, 6 retrospective cohort studies, and 7 prospective cohort studies), and 10 out of 17 studies were included in the meta-analysis of proportions (4 case series studies, 2 retrospective cohort studies and 4 prospective cohort studies) (Fig. 2) (Adhikari et al. 2020 , Ayed et al. 2020 , Chen et al. 2020 , Curi et al. 2020 , Delahoy et al. 2020 , Grechukhina et al. 2020 , Knight et al. 2020 , Mattar et al. 2020 , Nayak et al. 2020 , Shmakov et al. 2020 , Wong et al. 2020 , Yan et al. 2020 , D'Antonio et al. 2021 , Group 2021 , Guo et al. 2021 , Sahin et al. 2021 , Singh et al. 2021 . All included studies were published from April 17, 2020, to February 20, 2021. Table 1 shows the characteristics of included studies. Subgroup analysis was done in women who miscarried before 12 weeks of gestation (8 studies) and those who J o u r n a l P r e -p r o o f miscarried before 22 weeks of gestation (3 studies). The study by Mattar et al. was included in both subgroup analyses since the study described 6 cases of COVID-19 in pregnant women <12 weeks and total of 7 cases in pregnant women <22 weeks gestation.

Chen et al. were the first to described miscarriage as a possible pregnancy outcome in . In this group of patients (Wuhan City, China), there were three spontaneous abortions, two ectopic pregnancies, and four induced abortions (all due to patients' concerns about COVID-19). The authors did not report the number of COVID-19 cases per trimester, being impossible to calculate the miscarriage rate. Pregnant women with non-severe COVID-19 had all of their losses in the first half of their pregnancy (Chen et al. 2020) . Another six studies included in this review described miscarriages in pregnant women infected with COVID-19, but the miscarriage rate could not be determined due to a lack of accurate data on the total number of pregnant women infected with SARS-CoV-2 in the first half of pregnancy (Adhikari et al. 2020 , Ayed et al. 2020 , Delahoy et al. 2020 , Nayak et al. 2020 , D'Antonio et al. 2021 , Guo et al. 2021 .

In a case series study of 116 patients, Yan et al. reported the miscarriage rate in pregnant women with COVID-19 for the first time. Before the 20th week of gestation, 8 out of 116 pregnant women were tested positive for COVID-19. The miscarriage rate among these eight pregnant women was 12.5% (n = 1/8, 95% CI 0.32-52.65) (Yan et al. 2020 ). Other authors have reported the following miscarriage rates (<22 weeks of gestation): 18.2% (n = 4/22, 95% CI 5.19-40.28) (Knight et al. 2020) , and 14.3% (n = 1/7, 95% CI 0.36-57.87) (Mattar et al. 2020 ).

Early miscarriage rates (<12 weeks) in pregnant women with COVID-19 diagnosed in the first trimester were 100% (n = 2/2, 95%CI 15.81-100) (Wong et al. 2020 ), 0% (n = 0/2, 95%CI 0-84.19) (Curi et al. 2020) , 19.4% (n = 6/31, 95%CI 7.45-37.47) (WAPM Group, 2020), 18.2% (n = 2/11, 95%CI 2.28-51.78) (Grechukhina et al. 2020) , 16.7% (n = 1/6, 95%CI 0.42-64.12) (Mattar et al. 2020), 9.2% (n = 12/130, 95%CI 4.86-15.57 ) (Sahin et al. 2021) , 40% (n = 2/5, 95%CI 5.27-85.34) (Shmakov et al. 2020) and 60 % (n = 3/5, 95%CI 14.66-94.73) (Singh et al. 2021) .

The study of the World Association of Perinatal Medicine (WAPM) group was the only one that determined the miscarriage rate based on the presence of COVID-19 symptoms in pregnant women. When symptomatic pregnant women (21.7%, n = 5/23) were compared to asymptomatic pregnant women (12.5%, n = 1/8) (p = 0.568), the miscarriage rates were not significantly different. In addition, pregnant women at high obstetric risk who had COVID-19 in the first half of pregnancy had a higher miscarriage rate than pregnant women at low obstetric risk (5.3% vs. 1.6%, p = 0.008) (D'Antonio et al. 2021).

To estimate the prevalence of miscarriage (<22 weeks) in patients with COVID-19, a total of 223 cases from 10 studies were pooled for the meta-analysis. The pooled proportion of miscarriage before 22 weeks gestation in pregnant women with COVID-19 was 15.3% (95% CI 10.95 to 20.59) and 23.1% (95% CI 13.17 to 34.95) using fixed and random effects models, respectively (Fig. 3) . The included studies showed significant heterogeneity, with I 2 being 58.3% (95% CI 16.01 to 79.31, P=0.010) (Fig. 3) .

Additionally, modest publication bias was noticed (Egger's test, 95% CI 0.623 to 3.307, P=0.0097; Begg's test Kendall's tau -0.2501, P=0.314).

A total of 8 studies investigating the COVID-19 cases in pregnant women <12 weeks gestation were included in this analysis. To estimate the prevalence of early miscarriage (<12 weeks) in patients with COVID-19, a total of 192 cases were pooled for the meta-analysis. The pooled proportion of miscarriage before 12 weeks gestation in pregnant women with COVID-19 was 14.9% (95% CI 10.3 to 20.6) and 26.7% (95% CI 13.1 to 43.0) using fixed and random effects models, respectively (Fig. 4) . However, the included studies showed substantial heterogeneity, with I 2 being 67.2% (95% CI 30.93 to 84.47, P=0.003) (Fig. 4) Three studies included pregnant women under 22 weeks gestation without specifying weeks miscarriage being <12 weeks. To estimate the prevalence of miscarriage (<22 weeks) in patients with COVID-19, a total of 37 cases were pooled for the metaanalysis. The pooled proportion of miscarriage before 22 weeks gestation in pregnant women with COVID-19 was 18.5% (95% CI 8.04 to 33.98) using both fixed and random effects models, respectively. The included studies showed low heterogeneity, with I 2 being 0% (95% CI 0.0 to 0.0, P=0.977) (Fig. 5) 

The research on the effects of viral respiratory infections on pregnancy, particularly during the first half of pregnancy, has been inconsistent. At the beginning of the COVID-19 pandemic, it was speculated that SARS-CoV-2 infection could increase the risk of miscarriage based on small studies conducted during previous SARS and MERS outbreaks (Favre et al. 2020) . The maternal influenza A subtype H1N1 infection can be fatal to pregnant women, inducing inflammatory immune responses similar to SARS-CoV-2 infection. A meta-analysis of 17 studies involving 2,351,204 cases published recently found that H1N1 infection increased the risk of stillbirth (Relative risk = 3.62, 95% CI: 1.60-8.20) (Wang et al. 2021) . In addition, a large Norwegian study noted that maternal influenza-like illness during pregnancy increases the risk of miscarriage (Adjusted hazard ratio = 2.28 [95% CI 1.45-3.59]) (Gunnes et al. 2020) .

Miscarriage is an unintentional pregnancy loss happening before 12 weeks (early miscarriage) or between 12 and 22 weeks (late miscarriage). The overall miscarriage rate before 20 weeks gestation ranges from 10% to 26% (Anon 2012, Anon 2018, Dugas and Slane 2021) with the rate increasing with the woman's age, reaching around 53% in women aged 45 and up (Kolte et al. 2015 , Pinar et al. 2018 . In this study, the pooled proportion of miscarriage (<22 weeks) in pregnant women with COVID-19 was 15.3% (95% CI 10.95 to 20.59) and 23.1% (95% CI 13.17 to 34.95) using fixed and random effects models, respectively. Thus the miscarriage rate of COVID-19 cases seems to be in the range of the normal pregnant population. Since most studies were case series studies without proper controls or only including COVID-19 cases, we were not able to compare miscarriage rates between COVID-19 positive and negative pregnant women. The findings should be interpreted cautiously, given the small number of cases and the heterogeneity among the included cases. cumulative incidence of COVID-19 was also compared in women who had miscarriages (n = 100) and those who were pregnant at the time of the study (controls, n = 125). No difference was detected in the cumulative incidence of COVID-19 between the miscarriage group (11/100, 11%) and controls (12/125, 9.6%) (p = 0.73) (Cosma et al. 2021) . Based on these studies, SARS-CoV-2 infection during the first trimester of pregnancy does not seem to predispose to early pregnancy loss.

Interestingly, the presence of symptoms during the acute phase of COVID-19, plasma viral load, disease severity, and the presence of obstetrical risk factors appear to increase the risk of miscarriage in pregnant women infected with SARS-CoV-2.

However, the studies included in this review did not adequately assess the relationship between the clinical features of pregnant women with COVID-19 and the risk of miscarriage, and the majority of them are small cohorts or case series studies to assess the 

None of the authors have a conflict of interest in this work. 

Pregnancy outcomes among women with and without severe acute respiratory syndrome coronavirus 2 infection

ACOG Practice Bulletin No. 200: Early pregnancy loss

Systemic and uteroplacental renin--angiotensin system in normal and pre-eclamptic pregnancies

Maternal and perinatal characteristics and outcomes of pregnancies complicated with COVID-19 in Kuwait

Expression of severe acute respiratory syndrome coronavirus 2 cell entry genes, angiotensin-converting enzyme 2 and transmembrane protease serine 2, in the placenta across gestation and at the maternal-fetal interface in pregnancies complicated by preterm birth or preeclampsia

Persistence of SARS-COV-2 in body fluids: A bystander or whistle blower

SARS-COV-2, SARS-COV, and MERS-COV viral load dynamics, duration of viral shedding, and infectiousness: A systematic review and metaanalysis

Severe Acute Respiratory Syndrome Coronavirus 2 RNA Detected in Blood Donations

Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China

Coronavirus disease 2019 and first-trimester spontaneous abortion: A case-control study of 225 pregnant patients

Single-cell RNA expression profiling of SARS-CoV-2-related ACE2 and TMPRSS2 in human trophectoderm and placenta

Coronavirus infection in a high-risk obstetrical population of the South Bronx

Maternal and perinatal outcomes in high vs low riskpregnancies affected by SARS-CoV-2 infection (phase-2): The WAPM (World Association of Perinatal Medicine) working group on COVID-19

Characteristics and Maternal and Birth Outcomes of Hospitalized Pregnant Women with Laboratory-Confirmed COVID-19 -COVID-NET, 13 states

ACE2, PMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19

Miscarriage

SARS-CoV-2 viral load is associated with increased disease severity and mortality

SARS-CoV-2 detection in the pericardial fluid of a patient with cardiac tamponade

2019-nCoV epidemic: What about pregnancies?

Report of Positive Placental Swabs for SARS-CoV-2 in an Asymptomatic Pregnant Woman with COVID-19

The role of infection in miscarriage

Coronavirus disease 2019 pregnancy outcomes in a racially and ethnically diverse population

Seasonal and pandemic influenza during pregnancy and risk of fetal death: A Norwegian registry-based cohort study

Case series of 20 pregnant women with 2019 novel coronavirus disease in Wuhan

SARS-CoV-2 infection of the placenta

SARS-CoV-2 Detected in Cerebrospinal Fluid by PCR in a Case of COVID-19 Encephalitis

Characteristics and outcomes of pregnant women admitted to hospital with confirmed SARS-CoV-2 infection in UK: National population based cohort study

Terminology for pregnancy loss prior to viability: A consensus statement from the ESHRE early pregnancy special interest group

Immunological modes of pregnancy loss: Inflammation, immune effectors, and stress

Clinical Characteristics and Results of Semen Tests Among Men with Coronavirus Disease

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration

Why are pregnant women susceptible to covid-19? An immunological viewpoint

Pregnancy Outcomes in COVID-19: A Prospective Cohort Study in Singapore

First Detection of SARS-CoV-2 by Real-Time Reverse Transcriptase-Polymerase Chain Reaction Assay in Pleural Fluid

Transmission of SARS-CoV-2: A Review of Viral, Host, and Environmental Factors

One year update on the COVID-19 pandemic: Where are we now?

A first case of meningitis/encephalitis associated with SARS-Coronavirus-2

SARS-CoV-2 Infection and COVID-19 During Pregnancy: A Multidisciplinary Review

Impact of the Coronavirus Infection in Pregnancy: A Preliminary Study of 141 Patients

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Early Pregnancy Losses: Review of Nomenclature, Histopathology, and Possible Etiologies

Evaluation and treatment of recurrent pregnancy loss: A committee opinion

The role of the renin-angiotensin system in regulating endometrial neovascularization during the peri-implantation period: Literature review and preliminary data

COVID-19 pandemic effect on early pregnancy: Are miscarriage rates altered, in asymptomatic women?

Updated experience of a tertiary pandemic center on 533 pregnant women with COVID-19 infection: A prospective cohort study from Turkey

When will the COVID-19 pandemic end?

A structured review of placental morphology and histopathological lesions associated with SARS-CoV-2 infection

Persistence of SARS-CoV-2 in the first trimester placenta leading to transplacental transmission and fetal demise from an asymptomatic mother

Clinical course of novel COVID-19 infection in pregnant women

An Experimental Model for Peri

Pregnancy Loss and Proposed Interventions to Optimize Outcomes

Maternal and Neonatal Outcomes of COVID-19 in Pregnancy: A Single-Centre Observational Study

Consistent Detection of 2019 Novel Coronavirus in Saliva

Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies

Fetal and placental infection with SARS-CoV-2 in early pregnancy

The vasoactive peptide angiotensin-(1-7), its receptor Mas and the angiotensin-converting enzyme type 2 are expressed in the human endometrium

SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development

The effect of influenza virus infection on pregnancy outcomes: A systematic review and meta-analysis of cohort studies

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

WAPM (World Association of Perinatal Medicine) Working Group on COVID-19, 2021. Maternal and perinatal outcomes of pregnant women with SARS-CoV-2 infection

Expression of SARS-CoV-2 receptor ACE2 and the protease TMPRSS2 suggests susceptibility of the human embryo in the first trimester

Miscarriage Risk in COVID-19 Infection

2021. WHO Coronavirus Disease (COVID-19) Dashboard

The outbreak of COVID-19: An overview

Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases from the Chinese Center for Disease Control and Prevention

SARS-CoV-2 in the ocular surface of COVID-19 patients

Coronavirus disease 2019 in pregnant women: A report based on 116 cases

Women with multiple implantation failures and recurrent pregnancy losses have increased peripheral blood T cell activation

Update: Characteristics of Symptomatic Women of Reproductive Age with Laboratory-Confirmed SARS-CoV-2 Infection by Pregnancy Status -United States

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

 Knight et al., 2020 June 8, 2020 (United  Kingdom) PCS c (n=427) 18.2% (4/22) (5. 19 -40.28) The study included 22 (5%) patients <22 weeks, 60 (14%) 22-27 weeks, 64 (15%) 28-31 weeks, 106 (25%) 32-36 weeks, 142 (33%) >37 weeks, 30 (7%) peripartum, and 3 (0.7%) missing data. Four women had a miscarriage, at a range of 10 to 19 weeks gestation. Symptomatic patients (all pregnant women were admitted to hospital with confirmed SARS-CoV-2 infection). Nayak et al., 2020 July 7, 2020